International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

Levitan, 1999, Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data, Medicine (Baltimore), 78, 285, 10.1097/00005792-199909000-00001 Heit, 2000, Risk factors for deep vein thrombosis and pulmonary embolism: a population‐based case‐control study, Arch Intern Med, 160, 809, 10.1001/archinte.160.6.809 Chew, 2006, Incidence of venous thromboembolism and its effect on survival among patients with common cancers, Arch Intern Med, 166, 458, 10.1001/archinte.166.4.458 Trousseau A. Plegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel‐Dieu, Paris 1865; 5: 281–332. Khorana, 2007, Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients, Cancer, 15, 110 Khorana, 2007, Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy, J Thromb Haemost, 5, 632, 10.1111/j.1538-7836.2007.02374.x Prandoni, 2002, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, 100, 3484, 10.1182/blood-2002-01-0108 Elting, 2004, Outcomes and cost of deep venous thrombosis among patients with cancer, Arch Intern Med, 164, 1653, 10.1001/archinte.164.15.1653 Mandalà, 2006, Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM), Crit Rev Oncol Hematol, 59, 194, 10.1016/j.critrevonc.2006.05.001 Lyman, 2007, American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer, J Clin Oncol, 25, 5490, 10.1200/JCO.2007.14.1283 Farge, 2010, 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group, Crit Rev Oncol Hematol, 73, 31, 10.1016/j.critrevonc.2008.12.004 Geerts, 2008, Prevention of venous thromboembolism: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines (8th Edition), Chest, 133, 381S, 10.1378/chest.08-0656 Kearon, 2008, Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines (8th Edition), Chest, 133, 454S, 10.1378/chest.08-0658 Palumbo, 2008, Prevention of thalidomide‐ and lenalidomide‐associated thrombosis in myeloma, Leukemia, 22, 414, 10.1038/sj.leu.2405062 Venous thromboembolic disease NCCN guidelines V2.2009. 2009. http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf Accessed on 8 August 2011. Mandala, 2009, Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations, Ann Oncol, 20, iv82 Debourdeau, 2009, 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group, Ann Oncol, 20, 1459, 10.1093/annonc/mdp052 Mandalà, 2011, Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines, Ann Oncol, 22, vi85, 10.1093/annonc/mdr392 Cohen, 2008, Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross‐sectional study, Lancet, 371, 387, 10.1016/S0140-6736(08)60202-0 Noble, 2008, Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta‐analysis, Lancet Oncol, 9, 577, 10.1016/S1470-2045(08)70149-9 Schulman, 2005, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients, J Thromb Haemost, 3, 692, 10.1111/j.1538-7836.2005.01204.x Schulman, 2010, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients, J Thromb Haemost, 8, 202, 10.1111/j.1538-7836.2009.03678.x Guyatt, 2008, Rating quality of evidence of and strength of recommandations, BMJ, 336, 1049, 10.1136/bmj.39493.646875.AE Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD Moore, 1981, Anticoagulants, venous thromboembolism and the cancer patient, Arch Surg, 116, 405, 10.1001/archsurg.1981.01380160021005 Clarke‐Pearson, 1983, Anticoagulation therapy for VTE in patients with gynaecologic malignancy, Am J Obstet Gynecol, 147, 369, 10.1016/S0002-9378(16)32227-X Krauth, 1987, Safety and efficacy of long‐term oral anticoagulation in cancer patients, Cancer, 59, 983, 10.1002/1097-0142(19870301)59:5<983::AID-CNCR2820590522>3.0.CO;2-O Calligaro, 1991, Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement, Ann Vasc Surg, 5, 186, 10.1007/BF02016754 Chan, 1992, Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy, Aust N Z J Med, 22, 119, 10.1111/j.1445-5994.1992.tb02789.x Debourdeau, 1996, Traitement anticoagulant classique de la maladie thromboembolique veineuse chez les patients cancéreux. A propos d’une série rétrospective de 71 patients, Rev Med Int, 17, 207, 10.1016/0248-8663(96)81247-1 Harrington, 1997, Cancer‐related thromboembolic disease in patients with solid tumours: a retrospective analysis, Ann Oncol, 8, 669, 10.1023/A:1008230706660 Bona, 2000, Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis, Am J Clin Oncol, 23, 71, 10.1097/00000421-200002000-00020 Hutten, 2000, Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis, J Clin Oncol, 18, 3078, 10.1200/JCO.2000.18.17.3078 Palareti, 2000, A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy, Thromb Haemost, 84, 805, 10.1055/s-0037-1614120 Vucic, 2002, Treatment of deep vein thrombosis with oral anticoagulants in patients with malignancy: prospective cohort study, Croat Med J, 43, 296 Hull, 2006, Long‐term low‐molecular‐weight heparin versus usual care in proximal‐vein thrombosis patients with cancer, Am J Med, 119, 1062, 10.1016/j.amjmed.2006.02.022 van Doormaal, 2009, Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials, Thromb Haemost, 101, 762, 10.1160/TH08-09-0563 Meyer, 2002, Comparison of low‐molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study, Arch Intern Med, 162, 1729, 10.1001/archinte.162.15.1729 Lee, 2003, Low‐molecular‐weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, N Engl J Med, 349, 146, 10.1056/NEJMoa025313 Deitcher, 2006, Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180‐day period, Clin Appl Thromb Hemost, 12, 389, 10.1177/1076029606293692 Romera, 2009, A randomised open‐label trial comparing long‐term sub‐cutaneous low‐molecular‐weight heparin compared with oral‐anticoagulant therapy in the treatment of deep venous thrombosis, Eur J Vasc Endovasc Surg, 37, 349, 10.1016/j.ejvs.2008.11.030 Lensing, 1995, Treatment of deep venous thrombosis with low‐molecular‐weight heparins, a meta‐analysis, Arch Intern Med, 155, 601, 10.1001/archinte.1995.00430060059007 Siragusa, 1996, Low‐molecular‐weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta‐analysis, Am J Med, 100, 269, 10.1016/S0002-9343(97)89484-3 Hettiarachchi, 1998, Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism, Curr Opin Pulm Med, 4, 220, 10.1097/00063198-199807000-00007 Gould, 1999, Low‐molecular‐weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta‐analysis of randomized, controlled trials, Ann Intern Med, 130, 800, 10.7326/0003-4819-130-10-199905180-00003 Dolovich, 2000, A meta‐analysis comparing low‐molecular‐weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency, Arch Intern Med, 160, 181, 10.1001/archinte.160.2.181 Rocha, 2000, Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta‐analysis, Haematologica, 85, 935 Quinlan, 2004, Low‐molecular‐weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta‐analysis of randomized, controlled trials, Ann Intern Med, 140, 175, 10.7326/0003-4819-140-3-200402030-00008 Mismetti, 2005, Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta‐analysis, Chest, 128, 2203, 10.1378/chest.128.4.2203 Akl, 2008, Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review, Cancer, 113, 1685, 10.1002/cncr.23814 Akl, 2011, Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Review), Cochrane Database Syst Rev, 6, CD006649 Mikkola, 1997, Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer, Am Heart J, 134, 603, 10.1016/S0002-8703(97)70041-3 Cohen, 1991, Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer, Surgery, 109, 12 Cohen, 1992, Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer, Cancer, 70, 1993, 10.1002/1097-0142(19921001)70:7<1993::AID-CNCR2820700731>3.0.CO;2-V Levin, 1993, Complications of therapy for venous thromboembolic disease in patients with brain tumors, Neurology, 43, 1111, 10.1212/WNL.43.6.1111 Hubbard, 1994, The Bird’s Nest Filter. An alternative to long‐term oral anticoagulation in patients with advanced malignancies, Am J Clin Oncol, 17, 115, 10.1097/00000421-199404000-00005 Schiff, 1994, Therapy of venous thromboembolism in patients with brain metastases, Cancer, 73, 493, 10.1002/1097-0142(19940115)73:2<493::AID-CNCR2820730240>3.0.CO;2-D Schwarz, 1996, Inferior vena cava filters in cancer patients: indications and outcome, J Clin Oncol, 14, 652, 10.1200/JCO.1996.14.2.652 Greenfield, 1997, Clinical results of Greenfield filter use in patients with cancer, Cardiovasc Surg, 5, 145, 10.1016/S0967-2109(97)00005-7 Ihnat, 1998, Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine?, J Vasc Surg, 28, 800, 10.1016/S0741-5214(98)70054-0 Schleich, 2001, Long‐term follow‐up of percutaneous vena cava filters: a prospective study in 100 consecutive patients, Eur J Vasc Endovasc Surg, 21, 450, 10.1053/ejvs.2001.1319 Jarrett, 2002, Inferior vena cava filters in malignant disease, J Vasc Surg, 36, 704, 10.1016/S0741-5214(02)00121-0 Wallace, 2004, Use of inferior vena caval filters and survival in patients with malignancy, Cancer, 101, 1902, 10.1002/cncr.20578 Zerati, 2005, Vena cava filters in cancer patients: experience with 50 patients, Clinics (Sao Paulo, Brazil), 60, 361, 10.1590/S1807-59322005000500003 Schunn, 2006, Inferior vena cava filter placement in late‐stage cancer, Vasc Endovasc Surg, 40, 287, 10.1177/1538574406291821 Monreal, 2004, Fixed dose low‐molecular‐weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study, J Thromb Haemost, 2, 1311, 10.1111/j.1538-7836.2004.00853.x López‐Beret, 2001, Low molecular weight heparin versus oral anticoagulants in the long‐term treatment of deep venous thrombosis, J Vasc Surg, 33, 77, 10.1067/mva.2001.109336 Iorio, 2003, Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomized comparisons with oral anticoagulants, J Thromb Haemost, 1, 1906, 10.1046/j.1538-7836.2003.00364.x Ferretti, 2006, Is recurrent venous thromboembolism after therapy reduced by low‐molecular‐weight heparin compared with oral anticoagulants?, Chest, 130, 1808, 10.1378/chest.130.6.1808 Louzada, 2009, Efficacy of low‐ molecular‐weight‐heparin versus vitamin K antagonists for long term treatment of cancer‐associated venous thromboembolism in adults: a systematic review of randomized controlled trials, Thromb Res, 123, 837, 10.1016/j.thromres.2008.09.002 Akl, 2008, Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer, Cochrane Database Syst Rev, 2, CD006650 Akl, 2008, Low‐molecular‐weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review, J Exp Clin Cancer Res, 27, 21, 10.1186/1756-9966-27-21 van Doormaal, 2010, Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: A subgroup analysis of the VANGOGH‐DVT trial, Thromb Haemost, 104, 86, 10.1160/TH09-12-0870 Siragusa, 2010, The optimal duration of anticoagulant therapy In patients with cancer‐related deep vein thrombosis: the advantage of using residual vein thrombosis (the Cancer‐DACUS Study), Blood, 116, 190, 10.1182/blood.V116.21.190.190 Carrier, 2009, Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients, J Thromb Haemost, 7, 760, 10.1111/j.1538-7836.2009.03326.x Shukla, 2008, Postoperative deep vein thrombosis in patients with colorectal cancer, Ind J Gastroenterol, 27, 71 Mismetti, 2001, Meta‐analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery, Br J Surg, 88, 913, 10.1046/j.0007-1323.2001.01800.x Einstein, 2007, Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review, Gynecol Oncol, 105, 813, 10.1016/j.ygyno.2007.03.004 Oates‐Whitehead, 2003, Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery, Cochrane Database Syst Rev, 4, CD003679 1997, Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double‐blind randomized multicentre trial with venographic assessment, Br J Surg, 84, 1099 Baykal, 2001, Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double‐blind clinical study, Eur J Gynaecol Oncol, 22, 127 McLeod, 2001, Subcutaneous heparin versus low‐molecular‐weight heparin as thromboprophylaxis in patients undergoing colorectal surgery, Ann Surg, 233, 438, 10.1097/00000658-200103000-00020 Akl, 2008, Low‐molecular‐weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta‐analysis, Arch Intern Med, 168, 1261, 10.1001/archinte.168.12.1261 Agnelli, 2005, Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high‐risk abdominal surgery, Br J Surg, 92, 1212, 10.1002/bjs.5154 Simonneau, 2006, A randomized study comparing the efficacy and safety of nadroparin 2850 IU, J Thromb Haemost, 4, 1693, 10.1111/j.1538-7836.2006.02083.x Bergqvist, 1995, Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 vs 5000 Xa IU in 2070 patients, Br J Surg, 82, 496, 10.1002/bjs.1800820421 Bergqvist, 2002, Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer, N Engl J Med, 346, 975, 10.1056/NEJMoa012385 Lausen, 1998, Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis, Eur J Surg, 164, 657, 10.1080/110241598750005534 Rasmussen, 2006, Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open‐label study, J Thromb Haemost, 4, 2384, 10.1111/j.1538-7836.2006.02153.x Kakkar, 2010, Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study, J Thromb Haemost, 8, 1223, 10.1111/j.1538-7836.2010.03892.x Akl, 2008, Extended perioperative thromboprophylaxis in patients with cancer, Thromb Haemost, 100, 1176, 10.1160/TH08-04-0218 Maxwell, 2001, Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial, Obst Gynecol, 98, 989 Turpie, 1989, Prevention of deep vein thrombosis in potential neurosurgical patients; a randomized trial comparing graduated compression stockings plus intermittent pneumatic compression with control, Arch Med Intern, 149, 679, 10.1001/archinte.1989.00390030131025 Dickinson, 1998, Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors, Neurosurgery, 43, 1074, 10.1097/00006123-199811000-00039 Collen, 2008, Prevention of venous thromboembolism in neurosurgery: a metaanalysis, Chest, 134, 237, 10.1378/chest.08-0023 Bergmann, 1996, A multicenter randomized double‐blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in‐patients bedridden for an acute medical illness, Thromb Haemost, 76, 529, 10.1055/s-0038-1650617 Harenberg, 1996, Subcutaneous low‐molecular‐weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients, Haemostasis, 26, 127 Lechler, 1996, The venous thrombotic risk in non‐surgical patients: epidemiological data and efficacy/safety profile of a low‐molecular‐weight heparin (enoxaparin). The PRIME Study Group, Haemostasis, 26, 49 Kleber, 2003, Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease, Am Heart J, 145, 614, 10.1067/mhj.2003.189 Dahan, 1986, Prevention of deep vein thrombosis in elderly medical in‐patients by a low molecular weight heparin: a randomized double‐blind trial, Haemostasis, 16, 159 Samama, 1999, A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients, N Engl J Med, 341, 793, 10.1056/NEJM199909093411103 Leizorovicz, 2004, Randomized, placebo‐controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients, Circulation, 110, 874, 10.1161/01.CIR.0000138928.83266.24 Cohen, 2006, Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial, BMJ, 332, 325, 10.1136/bmj.38733.466748.7C Meister, 2008, Comparison of low‐molecular‐weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia, Pediatr Blood Cancer, 50, 298, 10.1002/pbc.21222 Mitchell, 2003, Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l‐asparaginase for acute lymphoblastic leukemia, Thromb Haemost, 90, 235, 10.1160/TH02-11-0283 Riess, 2009, PROSPECT‐CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy, ASCO Maraveyas, 2012, Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer, Eur J Cancer, 48, 1283, 10.1016/j.ejca.2011.10.017 Haas, 2012, Low‐molecular‐weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer, Clin Appl Thromb Hemost, 18, 159, 10.1177/1076029611433769 Agnelli, 2009, Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo‐controlled, double‐blind study, Lancet Oncol, 10, 943, 10.1016/S1470-2045(09)70232-3 Perry, 2010, PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma, J Thromb Haemost, 8, 1959, 10.1111/j.1538-7836.2010.03973.x Verso, 2010, Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC‐2 studies, J Thromb Haemost, 8, 1649, 10.1111/j.1538-7836.2010.03901.x Zangari, 2004, Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation, Br J Haematol, 126, 715, 10.1111/j.1365-2141.2004.05078.x Ikhlaque, 2006, Efficacy of prophylactic warfarin for prevention of thalidomide‐related deep venous thrombosis, Am J Hematol, 81, 420, 10.1002/ajh.20625 Palumbo, 2011, Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open‐label, randomized trial, J Clin Oncol, 10, 29 El Accaoui, 2007, Thalidomide and thrombosis, Thromb Haemost, 97, 1031, 10.1160/TH06-09-0494 Hicks, 2008, A meta‐analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma, Cancer Treat Rev, 34, 442, 10.1016/j.ctrv.2008.02.003 Schmidt, 2002, Low molecular weight heparin for deep vein thrombosis in glioma patients, J Neurol, 249, 1409, 10.1007/s00415-002-0855-5 Altschuler, 1990, The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors, Neurosurgery, 27, 74, 10.1227/00006123-199007000-00010 Cerrato, 1978, Deep vein thrombosis and low‐dose heparin prophylaxis in neurosurgical patients, J Neurosurg, 49, 378, 10.3171/jns.1978.49.3.0378 Constantini, 2001, Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double‐blind study, J Neurosurg, 94, 918, 10.3171/jns.2001.94.6.0918 Macdonald, 2003, Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy, Surg Neurol, 59, 363, 10.1016/S0090-3019(03)00111-3 Melon, 1991, Deep venous thrombosis prophylaxis by LMWH in neurosurgical patients, Anesthesiology, 75, A214, 10.1097/00000542-199109001-00214 Nurmohamed, 1996, Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery, Thromb Haemost, 75, 233, 10.1055/s-0038-1650250 Agnelli, 1998, Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery, N Engl J Med, 339, 80, 10.1056/NEJM199807093390204 Goldhaber, 2002, Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis, Chest, 122, 1933, 10.1378/chest.122.6.1933 Iorio, 2000, Low‐molecular‐weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta‐analysis, Arch Intern Med, 160, 2327, 10.1001/archinte.160.15.2327